Is this you? Create Your Porfile
Avatar

H. Kantarjian

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where H. Kantarjian is active.

Explore More

Publication

Featured researches published by H. Kantarjian.

Journal of Clinical Oncology | 2010

Analysis of survival of older patients with frontline AML treated with clofarabine with or without low-dose cytarabine or intermediate-dose cytarabine: A matched cohort comparison.

S. Faderl; F. Ravandi Kashani; G. Borthakur; T. M. Kadia; E. Jabbour; G. Garcia-Manero; M. Brandt; S. Pierce; H. Kantarjian

6551 Background: Outcome following standard or higher-dose cytarabine plus an anthracycline (e.g., “3+7”) in older patients (pts) is historically poor with low survival rates and substantial toxici...

Journal of Clinical Oncology | 2010

Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL).

D. A. Thomas; S. M. O'Brien; S. Faderl; F. Ravandi Kashani; W. G. Wierda; M. Andreeff; R. S. Garris; R. E. Champlin; J. E. Cortes; H. Kantarjian

Journal of Clinical Oncology | 2010

Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies.

A. Dean; M. Talpaz; H. Kantarjian; S. Faderl; E. Jabbour; F. Ravandi Kashani; S. M. O'Brien; M. Rosenblum; J. E. Cortes

Journal of Clinical Oncology | 2010

Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML).

G. Borthakur; E. Jabbour; X. Wang; J. E. Cortes; F. Ravandi Kashani; T. M. Kadia; J. Bass; M. Brandt; H. Kantarjian

Journal of Clinical Oncology | 2009

Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML)

F. Ravandi Kashani; J. E. Cortes; S. Faderl; D. Jones; A. Byrd; M. Brandt; G. Garcia-Manero; M. Levis; M. Andreeff; H. Kantarjian

Journal of Clinical Oncology | 2010

Randomized study of decitabine versus conventional care (CC) in patients (pts) with intermediate- and high-risk acute myeloid leukemia (AML) in first or subsequent complete remission (CR).

F. Ravandi Kashani; J. Jorgensen; S. Faderl; J. Issa; J. Autry; G. Garcia-Manero; G. Borthakur; X. Huang; J. E. Cortes; H. Kantarjian

Journal of Clinical Oncology | 2010

Impact of neutropenia on the outcome of decitabine (DAC) treatment in patients (pts) with myelodysplastic syndrome (MDS).

N. Pemmaraju; H. Kantarjian; S. Faderl; G. Garcia-Manero; T. M. Kadia; G. Borthakur; J. E. Cortes; F. Ravandi Kashani

Journal of Clinical Oncology | 2010

Phase II study of hyper-CVAD followed by nelarabine consolidation in newly diagnosed patients with T cell acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL).

C. E. Vigil; H. Kantarjian; D. A. Thomas; S. M. O'Brien; F. Ravandi Kashani; C. A. Koller; J. A. Burger; R. S. Garris; M. D. Baccus; S. Faderl

Journal of Clinical Oncology | 2010

Hypocellular acute myeloid leukemia: Better or worse prognosis.

A. Al-Kali; S. N. Konoplev; E. Lin; T. M. Kadia; S. Faderl; F. Ravandi Kashani; M. Ayoubi; M. Brandt; H. Kantarjian; G. Borthakur

Journal of Clinical Oncology | 2010

A randomized study of two dose levels of intravenous (IV) clofarabine (CLO) in the treatment of patients (pts) with higher-risk myelodysplastic syndrome (MDS).

E. Jabbour; H. Kantarjian; G. Garcia-Manero; F. Ravandi Kashani; G. Borthakur; Z. Estrov; V. Gandhi; A. Byrd; M. Kwari; S. Faderl

Explore More

Collaboration

Dive into the H. Kantarjian's collaboration.

Explore More
Researchain Logo
Decentralizing Knowledge